IJCNP, Volume 2, Issue 12, 2024 ISSN: 2995-536X
https://medicaljournals.eu/index.php/IJCNP

INTERNATIONAL JOURNAL OF COGNITIVE NEUROSCIENCE AND PSYCHOLOGY

RELEVANCE AND PROSPECTS OF THE SEARCH FOR DRUGS WITH ANXIOLYTIC ACTIVITY

Durdona Kenzhaeva Elmurod qizi, Shakhrizoda Adizova Samandarovna, Kholida Normuminova Dilshod qizi, Ulugbek Toshboev Quyli ugli, Sokhib Rashidov Zamon ugli
Tashkent medical academy, Tashkent, Uzbekistan

Abstract: The most common category of mental illnesses is anxiety disorders, which have significant negative effects on both individuals and society as a whole. The increasing medical need to enhance the efficacy and adverse effect profile of current medications is driving the quest for new pharmacological therapies for these illnesses. Numerous novel compounds have advanced into clinical trials as a result of the massive amount of data produced by anxiolytic drug discovery investigations. These attempts have, however, had a dismal therapeutic consequence because promising outcomes with new medicines in rat research have rarely transferred into human effectiveness. Here, we examine the key findings from preclinical research over the previous half-century looking for novel medications that don't target the classic anxiety-associated GABA (γ-aminobutyric acid)–benzodiazepine system. The majority of these studies have concentrated on the serotonin, neuropeptide, glutamate, and endocannabinoid systems. We point up a number of important problems that might have impeded the field's advancement and make suggestions for future improvements in anxiolytic medication research.

Key words: Anxiety disorders, mental illnesses, GABA (γ-aminobutyric acid)–benzodiazepine system, psychiatric diseases, social anxiety disorder, therapeutic plants.

Introduction. Chronic, incapacitating diseases, anxiety disorders have a significant financial impact on both the individual and society. In Western nations, these conditions are the most commonly diagnosed neuropsychiatric illnesses. Anxiety disorders had the highest 12-month prevalence estimates (a total of 14%) among all psychiatric diseases, according to a recent 3-year multi-method study that covered 30 European nations and a population of more than 500 million. Post-traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorder, agoraphobia, social anxiety disorder (SAD), and specific phobias are the seven recognized anxiety disorders at this time [1,2,3]. The World Health Organization estimates that in 2015, 3.6% and 4.4% of the global population, respectively, were exposed to anxiety and depression. Between 2005 and 2015, the overall population with these disorders grew by 14.9% and 18.4%, respectively. In 2020, COVID-19 caused a considerable increase in the prevalence of anxiety and depression. Approximately 70% of patients with mental illnesses are healthy adults between the ages of 30 and 60. Both the successful execution of citizens' private lives and the population's regular working activities are hampered by this. These conditions are dynamic in nature, with new types of depression and anxiety emerging each and being included in the clinical classification of these illnesses [4,5,6,7]. Concerns about a link to early mortality have grown as a result of evidence of negative consequences, such as an increased incidence of dementia and other psychomotor impairments (daytime weariness, ataxia, falls, and traffic accidents), cancer, pneumonia, and other infections. Up until recently, the evidence supporting this was based on a limited number of studies that varied in terms of setting, sample (particularly age distribution), length of follow-up, drug type, source of drug usage data, and degree of control for confounding (particularly from co-prescribing, smoking, socioeconomic status, physical and psychiatric comorbidity, and drug and alcohol misuse). Four studies (in younger samples) found evidence of considerably higher mortality, but two studies in older populations did not find a statistically significant link between benzodiazepine usage and death after controlling for confounders [8-16]. Although the Diagnostic and Statistical Manual of Mental Disorders is now undergoing

revision, it should be remembered that the classification of anxiety disorders is always changing. The usefulness of drawing rigid categorical distinctions across neuropsychiatric illnesses has also come up for discussion again; some authors contend that these distinctions fall along a dimensional range. It is obvious that efforts to model and create medications for certain conditions are complicated by the constantly shifting diagnostic picture. Failures in the clinical trial design for new anxiolytics could make this worse. Other writers have critically examined whether anxiolytic trials have been properly constructed to detect a decent efficacy of innovative treatments for mood and anxiety disorders, even if it is outside the purview of our competence to rate the fidelity of clinical trials [17,18,19]. Lack of a sufficient explanation of the pathogenic mechanisms behind neuropsychiatric illnesses like anxiety disorders is another well-discussed problem that complicates neuropsychiatric medication research. Finding trustworthy biochemical biomarkers or genetic variants that can be used to diagnose anxiety disorders and help predict treatment outcomes is still a significant challenge, despite a growing understanding that emotional disorders are caused by a combination of genetic and environmental risk factors [20,21]. The field has been viewed as a failure in spite of this vigorous preclinical research effort to discover novel anxiolytics. We evaluate the current status of anxiolytic medication discovery at this pivotal point in time in this review. We first present the tests and models of anxiety-like behaviors that have been most frequently used to find and assess new anxiolytic drugs in order to set the preclinical literature in some context. We then move on to the primary goal of our review, which is to find new anxiolytic medications that don't target the GABA–benzodiazepine system by analyzing a database that includes almost all preclinical research that has been published in the last 50 years using animal models. We concentrate on the serotonin, neuropeptide, glutamate, and endocannabinoid systems, which are the most thoroughly researched neurotransmitter systems. After examining this literature, we point out some of the main problems that might have prevented advancement and make suggestions for future improvements in anxiolytic drug discovery [1,2,3,5-11].

The main purpose of this analyzed manuscript is to conduct a brief review of the literature, taking into account the relevance and prospects of searching for drugs with anxiolytic activity.

Important medications with anxiolytic activities. According to the World Health Organization, 10% of people worldwide suffer from anxiety of some kind, while 30% of adults worldwide suffer from insomnia. A greater demand for organically derived compounds with less side effects has resulted from the serious negative effects of traditional medications used to treat anxiety and insomnia, including abuse, addiction, amnesia, and cognitive and sexual dysfunction. Concurring to World Wellbeing Organization (WHO) inquire about, the number of restorative plants utilized for helpful purposes around the world is roughly 20,000. Another WHO information is that around 4 billion individuals world-wide attempt to illuminate their wellbeing issues utilizing home grown drugs within the to begin with put. The three most vital variables within the utilize of restorative plants are quality, viability, and security, which are comparable to those of routine solutions. In this regard, it is essential to know the history of therapeutic plants utilized among the individuals, to record the existing ethnobotanical data some time recently it vanishes totally, and to analyze its adequacy and security in todays conditions. Numerous cutting edge drugs such as taxol, vinblastine, quinine, and artemisinin, are based on conventional medication and ethnopharmacology [2-8]. Hence, it is critical deductively demonstrate the adequacy of plants utilized in conventional medication and to distinguish the compound(s) mindful for the impact. All through history, plants have been the foremost vital common assets that individuals have utilized in nearly each angle of their lives, such as chasing, paying regard for devout customs, getting nourishment and protect, and understanding wellbeing issues. Dioscorides, who lived in Anatolia, included point by point data on the utilize of 500 therapeutic plants and drugs arranged from these plants in his 5-volume work can be considered as the primary pharmacopoeia. The utilize of plants as solutions begun within the early 19th century with extraction of morphine from opium and the consequent separation of compounds such as cocaine, codeine, digitoxin and quinine, in other words, the confinement of bioactive compounds from therapeutic plants. The utilize of plants for restorative purposes is the starting of the street to present day pharmaceutical nowadays [28-35].

Anxiolytic sedate revelation, whether it is centered on a single target or on numerous targets, will be incredibly encouraged by concerted endeavors to illustrate the basic neurobiology of uneasiness. distant better;A much better;A higher;A stronger;An improved">A higher understanding of uneasiness at this level would give the establishment for a sound, mechanism-based approach for planning anxiolytics. Fear termination has already been specified as an model of a degree that's behaviourally supported by an amazing understanding of the basic neural frameworks and circuits. The neural circuitry subserving conduct within the classic uneasiness tests has, by differentiate, not been well defined. This may be changing, be that as it may, with the application of powerful unused methods, such as optogenetics and can be advance supported by the consolidation of propels within the imaging of the living brain of rodents. In parallel, advancing innovations for considering the neuropathophysiology of uneasiness in people, from dissemination tensor imaging and fMRI to genome sequencing, will serve to illuminate and coordinate the preclinical inquire about. An ideal procedure will coordinated discoveries from people and creatures in an exertion to synergize merged, cross-translational bolster for the clinical potential of an anxiolytic target [24-29].

An effective experimental model of anxiety has previously been thoroughly verified for use in studies involving humans. The physiological signs of anxiety that can be accurately detected as alterations in the startle reflex serve as the foundation for this model, which was directly adapted from research on animals. Involuntary whole-body reactions brought on by abrupt, powerful stimuli are known as the startle reflex. It is employed in a number of experimental models to investigate fear-potentiation, pre-pulse inhibition, sensitization, and habituation. The increase in startle response that occurs when anticipating temporally unpredictable adverse stimuli is known as anxiety-potentiated startle (APS). It is a continuation of a long-term condition of anxiousness. Importantly, it has been demonstrated that this model can assist in identifying and screening potential anxiolytics. In order to help drug developers make the critical go/no-go choice prior to starting a clinical trial, this review will show how APS in humans could improve the early stages of drug development by offering information on the anxiolytic qualities of novel compounds in humans [23-27].

The rationale behind the experimental model of anxiety in healthy humans is as follows: After a promising molecule is identified through basic research, its potential anxiolytic properties are tested in animals, and if deemed to have the preliminary requirements for further testing, the feasibility of moving to humans is tested. The drug's dosage, side effects, and mode of administration are evaluated in healthy humans, and if it passes these initial steps, it is recommended for clinical drug trials. At this point, there is a glaring gap: evidence of efficacy in animal models does not always translate into efficacy in humans. We contend that this information can be easily obtained by using an experimental model of anxiety in healthy humans [11-19].

Anxiety-potentiated startle to unpredictable threat. The development of experimental models of psychiatric disorders necessitates careful consideration of the targeted symptoms and their measurement. Fear and anxiety are two key symptoms that are relevant to anxiety disorders; they are distinct defensive responses to different types of threats: anxiety is a long-duration state of tension, caution, and vigilance in preparation for an uncertain future threat, while fear is a short-duration response, a surge of autonomic arousal required for fight-or-flight [20,21,22]. There are amazing translational models of fear utilizing Pavlovian (prompted) fear conditioning. Amid fear conditioning, a short-duration signal is over and over matched with an aversive jolt, making the prompt a solid indicator of peril. Consequent introduction of the prompt inspires a conditioned fear reaction, whereas the nonattendance of the signal signals security. Fear conditioning is valuable to create unused treatment procedures focusing on fear, but not uneasiness. The maintained cautious reaction that characterizes uneasiness can be evoked by erratic danger, i.e. a risk not signaled by a prompt. This may be finished with either conditioning strategies in people and creatures or verbal risk in people. Amid verbal risk, subjects are educated that an aversive boost will be conveyed unusually [23,24,25,26].

Discussion. Psychoactive chemicals have been used for ages to treat anxiety, which is a natural element of the human condition. The demand for anxiolytic medications in society and medicine has not decreased. The current overview discusses the ongoing medical need for novel antianxiety drugs

and gives a brief historical account of the discovery of modern-day anxiolytics, such as benzodiazepines. The application and significance of behavioral pharmacology in the preclinical development of anxiolytics are also covered in the paper. The variety of methods for developing a new class of anxiolytics that go beyond GABAA receptor potentiation and monoamine uptake blockage is then highlighted in the review [1,2,3]. Using human models of anxiety in healthy adults, this review presents a research approach that could fundamentally alter the hunt for novel anxiolytics. Pharmacotherapy for anxiety disorders is still not at its best, despite massive efforts in creating new pharmacological treatments. Clinical trials for the majority of animal-based potential anxiolytics end in failure. Before starting clinical trials, we suggest an extra screening step to aid in the selection of potential anxiolytics. Through the use of experimental models of anxiety in healthy individuals, this intermediary stage transfers the evidence supporting the potential anxiolytic properties of prospective medications from animals to humans. One reliable translational model of anxiety is anxiety-potentiated startle. It is a potential instrument for the discovery of anxiolytic drugs, according to a review of its face, concept, and predictive validity as well as its psychometric qualities in humans. In conclusion, the discovery of therapeutically useful anxiolytics may proceed more quickly and effectively if human models of anxiety are used [11,12,13,14,15]. The behavioral specificity of action of anxiolytics is then discussed, including the idea of developing an anxioselective drug, which targets anxiety without causing undesirable side effects like sedation and dependence. Additionally, the use of anxiolytics in the treatment of other conditions, such as substance use disorder, is briefly reviewed. Finally, a brief overview of the current state of anxiolytic drug development is given, concluding with the notion that, despite the availability of a variety of anxiolytic drugs, the lack of efficacy in certain patients and the side-effects and safety issues associated with some of these medications require alternative medications, and that current preclinical and clinical research is ongoing in order to find such compounds [18-22].

Conclusion. Anxiolytic diseases are severe medical conditions that are widespread and on the rise in many regions of the world. Better treatments are needed due to the rising prevalence of anxiety disorders, but despite encouraging developments, the search for novel anxiolytics appears to have come to a standstill. In order to help guide a more successful translational strategy in the future, we have provided a thorough analysis of the preclinical research that has been published thus far. Our goal is to present an unbiased assessment of the main trends, biases, and limits in the field.

We are hopeful that we may transition from the age of fear to the age of discovery with a new generation of preclinical investigations based on pathogenic rodent models that are circuit-informed and have robust, reciprocal translational ties to clinical research. It is evident from a historical review of anxiolytic medications that individuals utilize them often when they are accessible to reduce anxiety symptoms. Developing anxiolytic medications with fewer adverse effects, like drowsiness and dependence, has been an aim of contemporary drug discovery research since the beginning of modern mental care.

References.

1. Griebel G, Holmes A. 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013 Sep;12(9):667-87. doi: 10.1038/nrd4075.
2. Grillon C, Ernst M. A way forward for anxiolytic drug development: Testing candidate anxiolytics with anxiety-potentiated startle in healthy humans. Neurosci Biobehav Rev. 2020 Dec;119:348-354. doi: 10.1016/j.neubiorev.2020.09.024.
3. Kessler RC, Chiu W, Demler O, Walters EE, 2005. Prevalence, severity, and comorbidity of 12-month dsm-iv disorders in the national comorbidity survey replication. Archives of General Psychiatry 62, 617–627.
4. ugli , R. S. Z., ugli , T. A. A., ugli , B. Y. I., qizi , S. K. K., & ugli , M. I. Z. (2024). Features of Anti-Inflammatory Drugs and the Relevance of Creating New Anti-Inflammatory Drugs. American

Journal of Bioscience and Clinical Integrity, 1(11), 130–135. Retrieved from https://biojournals.us/index.php/AJBCI/article/view/320

5. Bandelow B, Michaelis S, 2015. Epidemiology of anxiety disorders in the 21st century. Dialogues in clinical neuroscience 17, 327–335.
6. Griebel G, Holmes A, 2013. 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 12, 667–687.
7. Zamon ugli, S. R., Mekhriddin qizi, M. N., Zokirzhon qizi, K. S., Akmal qizi, D. R., & Sirozhiddin qizi, U. N. (2024). Important Aspects and Risk Factors for Hypertension in the Environment and Adverse Climate. International Journal of Integrative and Modern Medicine, 2(11), 302–307. Retrieved from https://medicaljournals.eu/index.php/IJIMM/article/view/1220
8. Insel TR, Scolnick EM, 2006. Cure therapeutics and strategic prevention: raising the bar for mental health research. Molecular psychiatry 11, 11–17.
9. Papassotiropoulos A, de Quervain DJF, 2015. Failed drug discovery in psychiatry: time for human genome-guided solutions. Trends in Cognitive Sciences 19, 183–187.
10. Wittchen HU, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:655–679. doi: 10.1016/j.euroneuro.2011.07.018.
11. Weich S, Pearce H L, Croft P, Singh S, Crome I, Bashford J et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study BMJ 2014; 348 :g1996 doi:10.1136/bmj.g1996
12. Zamon ugli, S. R., Yorqinzhon ugli, N. Z., Abdurazak ugli, K. M., Mirodil qizi, S. M., & Yusufzhon ugli, K. Y. (2024). Insufficient of Existing Drugs Used for Diabetes Ii Types and the Need to Improve Them. International Journal of Integrative and Modern Medicine, 2(11), 294–301. Retrieved from https://medicaljournals.eu/index.php/IJIMM/article/view/1219
13. Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health2012;66:869-73.
14. ugli , S. R. Z., qizi, S. V. M., Madiyorovna , K. A., ugli , E. A. I., & qizi, S. N. Q. (2024). In Patients with Gastroduodenal Peptic Ulcer Disease, an Analysis of the Immunological Properties of H.Pylori Infection. International Journal of Alternative and Contemporary Therapy, 2(11), 93–99. Retrieved from https://medicaljournals.eu/index.php/IJACT/article/view/1214
15. Berry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med2013:1-8.
16. ugli , S. R. Z., ugli , S. S. S., qizi , D. U. O., qizi , G. N. B., & qizi , S. A. T. (2024). Modern Methods of Diagnosis of Osteoporosis, Advances in Treatment and Solutions to Existing Problems. International Journal of Alternative and Contemporary Therapy, 2(11), 100–106. Retrieved from https://medicaljournals.eu/index.php/IJACT/article/view/1215
17. Kupfer DJ, Regier DA. Neuroscience, clinical evidence, and the future of psychiatric classification in DSM-5. Am J Psychiatry. 2011;168:672–674. doi: 10.1176/appi.ajp.2011.11020219.
18. Craddock N, Owen MJ. The Kraepelinian dichotomy — going, going… but still not gone. Br J Psychiatry. 2010;196:92–95. doi: 10.1192/bjp.bp.109.073429.
19. Leucht S, Heres S, Davis JM. Considerations about the efficacy of psychopharmacological drugs. Nervenartz. 2011;82:1425–1430. doi: 10.1007/s00115-011-3349-9.

20. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry. 2010;167:509–527. doi: 10.1176/appi.ajp.2010.09101452.

21. Owen DR, Rupprecht R, Nutt DJ. Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety? J Psychopharmacol. 2013;27:119–122. doi: 10.1177/0269881112443746.

22. Jeffrey M. Witkin, James E. Barrett, ANXIOLYTICS: Origins, drug discovery, and mechanisms, Pharmacology Biochemistry and Behavior, Volume 245, 2024, 173858, https://doi.org/10.1016/j.pbb.2024.173858.

23. Grillon C, Hale E, Lieberman L, Davis A, Pine DS, Ernst M, 2015. The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle. Neuropsychopharmacol 40, 1064–1071.

24. Kaye JT, Fronk GE, Zgierska AE, Cruz MR, Rabago D, Curtin JJ, 2019. Acute prazosin administration does not reduce stressor reactivity in healthy adults. Psychopharmacology 236, 3371–3382.

25. Davis M, Walker DL, Miles L, Grillon C, 2010. Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs. anxiety. Neuropsychopharmacol 35, 105–135.

26. Grillon C, Baas JMP, Pine DS, Lissek S, Lawley M, Ellis V, Levine J, 2006b. The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle. Biol Psychiatry 60, 760–766.

27. Grillon C, Chavis C, Covington MS, Pine DS, 2009a. Two-week treatment with citalopram reduces contextual anxiety but not cued fear. Neuropsychopharmacol 34, 964–971.

28. Association AP, 2013. Diagnostic and statistical manual of mental disorders: DSM-5, 5th ed. American Psychiatric Association, Washingron, DC.

29. Luyten L, Vansteenwegen D, van Kuyck K, Gabriëls L, Nuttin B, 2011. Contextual conditioning in rats as an animal model for generalized anxiety disorder. Cogn Affect Behav Neurosci 11, 228–244.

30. Karpuz Ağören Büşra , Küpeli Akkol Esra , Çelik Ismail , Sobarzo-Sánchez Eduardo. Sedative and anxiolytic effects of Capparis sicula Duhamel: in vivo and in silico approaches with phytochemical profiling. Frontiers in Pharmacology, Volume 15, 2024,https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1443173, DOI=10.3389/fphar.2024.1443173

31. Т.Т.Ҳамроев, Н.М.Маматқулова, П.А.Нурмахмадова, С.З.Рашидов, И.Т.Абдиназаров, С.Д.Раҳимбоев, Н.Қ.Хидирова, У.М.Якубов. (2022). *Adonis turkestanica* ўсимлигининг экстракция жараёнида ҳосил бўлган қолдиқ моддаларнинг ўткир заҳарлилиги ва биологик фаоллигини скрининг тадқиқотларда ўрганиш. Eurasian journal of academic research, 2(12), 447–454. https://doi.org/10.5281/zenodo.7332870

32. Т.Т. Ҳамроев, Н.М. Маматқулова, З.И. Саноев, С.З. Рашидов, И.Т. Абдиназаров, П.А. Нурмахмадова, Н.Қ. Хидирова, У.М. Якубов. (2022). *Adonis turkestanica* ўсимлигининг экстракция жараёнида ҳосил бўлган қолдиқ моддаларнинг анксиолитик фаоллигини скрининг тадқиқотларда ўрганиш. Eurasian journal of medical and natural sciences, 2(12), 146–152. https://doi.org/10.5281/zenodo.7332882

33. Faydaoğlu, E., and Sürücüoğlu, M. S. (2011). Geçmişten günümüze tıbbi ve aromatik bitkilerin kullanılması ve ekonomik önemi. J. For. 11 (1), 52–67.

34. Leonti, M., and Casu, L. (2013). Traditional medicines and globalization: current and future perspectives in ethnopharmacology. Front. Pharmacol. 4 (4), 92–13. doi:10.3389/fphar.2013.00092

35. Pirintsos, S., Panagiotopoulos, A., Bariotakis, M., Daskalakis, V., Lionis, C., Sourvinos, G., et al. (2022). From traditional ethnopharmacology to modern natural drug discovery: a methodology discussion and specific examples. Molecules 27 (13), 4060. doi:10.3390/molecules27134060